CompletedPhase 2NCT02530320

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Studying Oligodendroglioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Grupo Español de Investigación en Neurooncología
Principal Investigator
Juan Manuel Sepúlveda
H. 12 de Octubre
Intervention
Palbociclib(drug)
Enrollment
34 enrolled
Eligibility
18 years · All sexes
Timeline
20152020

Study locations (11)

Collaborators

Pfizer

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02530320 on ClinicalTrials.gov

Other trials for Oligodendroglioma

Additional recruiting or active studies for the same condition.

See all trials for Oligodendroglioma

← Back to all trials